Ose

Edit

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi� in Ovarian Cancer ...

Nasdaq Globe Newswire 23 Apr 2026

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi� in Ovarian Cancer at the ASCO 2026 Meeting ... .

Edit

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer ...

Norfolk Daily News 23 Apr 2026

Nantes, France, April 23, 2026 – 7.30am CEST - OSE Immunotherapeutics SA (ISIN. FR0012127173; Mnemo. OSE), a ... .

Edit

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

Pharmiweb 23 Apr 2026

Nantes, France, April 23, 2026 – 7.30am CEST - OSE Immunotherapeutics SA (ISIN ... OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and ...

Edit

Notice suspension repositioning between Euronext Brussels and NYSE 2026 (4. Notice suspension repositioning between Euronext Brussels OSE NYSE 2026) (CMBTech NV)

Public Technologies 21 Apr 2026

). Limited Liability Company Registered offices.. De Gerlachekaai 20, 2000 Antwerpen. Enterprise number. 0860.402.767. 21 April 2026 SUSPENSION OF THE REPOSITIONING OF SHARES BETWEEN EURONEXT BRUSSELS,. EURONEXT OSLO AND THE NEW YORK STOCK EXCHANGE ... * * *.

Edit

Christine Horton, RDH, CHC, FAAOSH, CH-OSE Earns FADHA Fellowship from American Dental Hygienists’ Association for ...

GetNews 16 Apr 2026

- Christine Horton, RDH, CHC, FAAOSH, CH-OSE, Founder of Fusion Health Coaching ... Christine Horton, CHC, RDH, FAAOSH, CH-OSE ... Christine Horton, CHC, RDH, FAAOSH, CH-OSE, FADHA.

Edit

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of ...

Nasdaq Globe Newswire 15 Apr 2026

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meet ... .

Edit

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting

Pharmiweb 15 Apr 2026

Nantes, France, April 15, 2026 – 7.30am CEST - OSE Immunotherapeutics SA (ISIN ... About OSE Immunotherapeutics ... OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext ... www.ose-immuno.com.

Edit

OSE Immunotherapeutics Evolves its Leadership Team

Nasdaq Globe Newswire 14 Apr 2026

OSE Immunotherapeutics Evolves its Leadership Team . Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively ... .

Edit

OSE Immunotherapeutics fait �voluer son �quipe de direction

Nasdaq Globe Newswire 14 Apr 2026

OSE Immunotherapeutics fait �voluer son �quipe de direction ... .

Edit

OSE Immunotherapeutics to Present at Upcoming Investor Conferences (OSE Immunotherapeutics SA)

Public Technologies 23 Mar 2026

OSE IMMUNOTHERAPEUTICS. Nantes, France, March 23, 2026 - 6.00pm CET - OSE Immunotherapeutics SA (ISIN ... ABOUT OSE IMMUNOTHERAPEUTICS ... OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext ... www.ose-immuno.com ... OSE.

Edit

OSE Immunotherapeutics to Present at Upcoming Investor Conferences

Nasdaq Globe Newswire 23 Mar 2026

OSE Immunotherapeutics to Present at Upcoming Investor Conferences ... .

Edit

Tempi Train Disaster Trial Commences with 36 Defendants

Greek City Times 23 Mar 2026

Thirty-six defendants appeared before the Three-Member ....

Edit

New Name to be Listed on the OSE Securities Options Market (Japan Exchange Group Inc)

Public Technologies 19 Mar 2026

19, 2026 OSE New Name to be Listed on the OSE Securities Options Market ... OSE will continue to satisfy investors' needs by expanding its product lineup and offering new services.

Edit

10/03/2026 OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth (OSE Immunotherapeutics SA)

Public Technologies 10 Mar 2026

OSE Immunotherapeutics SA published this content on March 10, 2026, and is ...

Edit

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of ...

Nasdaq Globe Newswire 10 Mar 2026

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth ... .

Podcasts:

Latest News for: ose

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi� in Ovarian Cancer ...

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer ...

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

Notice suspension repositioning between Euronext Brussels and NYSE 2026 (4. Notice suspension repositioning between Euronext Brussels OSE NYSE 2026) (CMBTech NV)

Christine Horton, RDH, CHC, FAAOSH, CH-OSE Earns FADHA Fellowship from American Dental Hygienists’ Association for ...

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of ...

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting

OSE Immunotherapeutics Evolves its Leadership Team

OSE Immunotherapeutics fait �voluer son �quipe de direction

OSE Immunotherapeutics to Present at Upcoming Investor Conferences (OSE Immunotherapeutics SA)

OSE Immunotherapeutics to Present at Upcoming Investor Conferences

Tempi Train Disaster Trial Commences with 36 Defendants

New Name to be Listed on the OSE Securities Options Market (Japan Exchange Group Inc)

10/03/2026 OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth (OSE Immunotherapeutics SA)

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of ...

Article Search

EXPLORE WN.com